NYSEAMERICAN:SER Serina Therapeutics (SER) Stock Price, News & Analysis $1.88 +0.08 (+4.44%) As of 12:47 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Serina Therapeutics Stock (NYSEAMERICAN:SER) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Serina Therapeutics alerts:Sign Up Key Stats Today's Range$1.78▼$1.9050-Day Range$1.28▼$3.1552-Week Range$1.22▼$7.92Volume18,043 shsAverage Volume2.83 million shsMarket Capitalization$28.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama. Read More Serina Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreSER MarketRank™: Serina Therapeutics scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Serina Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Serina Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Serina Therapeutics is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSerina Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.60% of the float of Serina Therapeutics has been sold short.Short Interest Ratio / Days to CoverSerina Therapeutics has a short interest ratio ("days to cover") of 4.07.Change versus previous monthShort interest in Serina Therapeutics has recently increased by 9.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSerina Therapeutics does not currently pay a dividend.Dividend GrowthSerina Therapeutics does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.16 News SentimentSerina Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Serina Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for SER on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingSelling Shares Cluster Insider Buying2 insiders have purchased shares of Serina Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Insider Buying vs. Insider SellingIn the past three months, Serina Therapeutics insiders have sold 207.10% more of their company's stock than they have bought. Specifically, they have bought $37,802.00 in company stock and sold $116,090.00 in company stock.Percentage Held by Insiders17.00% of the stock of Serina Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.50% of the stock of Serina Therapeutics is held by institutions.Read more about Serina Therapeutics' insider trading history. Receive SER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Serina Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SER Stock News HeadlinesSerina Therapeutics (NYSEAMERICAN:SER) Director Acquires $17,700.00 in StockMay 27 at 5:28 AM | insidertrades.comSerina Therapeutics (NYSEAMERICAN:SER) Director Purchases $20,101.95 in StockMay 25 at 5:19 AM | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.May 28 at 1:00 AM | Porter & Company (Ad)Serina Therapeutics (NYSEAMERICAN:SER) Director Acquires $20,101.95 in StockMay 23, 2026 | insidertrades.comSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 14, 2026 | globenewswire.comSerina Therapeutics to Present at the 5th LNP Formulation & Process Development SummitApril 7, 2026 | globenewswire.comSerina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance PlanApril 2, 2026 | globenewswire.comSerina Therapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsMarch 25, 2026 | markets.businessinsider.comSee More Headlines SER Stock Analysis - Frequently Asked Questions How have SER shares performed this year? Serina Therapeutics' stock was trading at $2.87 at the beginning of the year. Since then, SER stock has decreased by 34.5% and is now trading at $1.88. How were Serina Therapeutics' earnings last quarter? Serina Therapeutics, Inc. (NYSEAMERICAN:SER) released its quarterly earnings data on Thursday, May, 14th. The company reported ($0.58) earnings per share for the quarter. How do I buy shares of Serina Therapeutics? Shares of SER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today5/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 2 days ago, SER's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:SER CIK1708599 WebN/A Phone(256) 327-9630Fax510-671-8619EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.18 million Net MarginsN/A Pretax Margin-16,358.46% Return on Equity-8,051.54% Return on Assets-155.08% Debt Debt-to-Equity Ratio0.24 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$130 thousand Price / Sales216.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book2.21Miscellaneous Outstanding Shares15,000,000Free Float12,448,000Market Cap$28.20 million OptionableN/A Beta1.15 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NYSEAMERICAN:SER) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersBNZI Breakout Watch: AI Growth Meets Turnaround Setup!Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, ...Huge Alerts | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe math on the SpaceX IPO is brokenSpaceX is expected to go public at a $1.75 trillion valuation. For investors to see a 10x return, the company ...Weiss Ratings | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | SponsoredThe AI Shakeout Is Coming — Most Investors Won’t SurviveEvery major tech shift follows the same pattern: hype, a brutal shakeout, then a handful of winners that take ...Prosperity Research | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, met...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Serina Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Serina Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
